REPRESSIT: A novel class of clinical immune checkpoint inhibitors

Informations projet

REPRESSIT

N° de convention de subvention: 101098965

DOI

10.3030/101098965

Date de signature de la CE 13 Mars 2023

Date de début 1 Mai 2023

Date de fin 30 Avril 2028

Financé au titre de

• The European Innovation Council (EIC)

Coût total

€ 2 896 496,25

Contribution de l’UE

€ 2 896 496,00

Coordonné par

STICHTING NEDERLANDSE WETENSCHAPPELIJK ONDERZOEK INSTITUTEN
Netherlands

Periodic Reporting for period 2 - REPRESSIT (REPRESSIT: A novel class of clinical immune checkpoint inhibitors)

Période du rapport: 2024-05-01 au 2025-08-31

Résumé du contexte et des objectifs généraux du projet

In the complex world of cancer, immune cells such as T cells and natural killer (NK) cells play a critical role in eliminating tumour cells, particularly after treatments like chemotherapy or radiation., However, these cells can become “switched off” by inhibitory immune receptors (IRs), leading to therapy resistance and disease relapse. Current checkpoint blockade therapies aiming to interfere with this off-switch have transformed outcomes for some patients but remain ineffective for many others, especially when tumours lack the ligands for these drugs to block.
In this context, the REPRESSIT consortium aims to overcome this limitation by directly targeting the root cause of IR signalling: IR tyrosine phosphorylation. Our strategy harnesses the natural phosphatase activity already present at the cell surface and redirects it to the vicinity of inhibitory receptors, selectively dampening their signalling This innovative induced-proximity approach aims to reinvigorate exhausted T and NK cells, both in the presence or absence of IR ligands. With a consortium of experts in IR biology, tumor immunology, protein engineering, biophysics, and proteomics, REPRESSIT aims to deliver a new generation of precision immunotherapies capable of overcoming resistance and broadening the reach of immune-based cancer treatment.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The consortium has successfully generated a portfolio of candidate molecules for our phosphatase recruitment–based checkpoint therapeutics. In parallel, we have established and optimized experimental platforms to refine these molecules and evaluate their ability to counteract inhibitory receptor (IR)-mediated T cell suppression. Candidate molecules targeting two distinct IRs have been developed and tested, alongside expanded libraries for a previously explored receptor.
Our in vitro and cell-based assays are now enabling systematic structure-function analyses, revealing key design principles for effective receptor inhibition via phosphatase recruitment. Importantly, RIPR-mediated receptor dephosphorylation has been demonstrated using single-molecule fluorescence microscopy in live cells, and proximity between phosphatases (CD45) and inhibitory receptors has been independently verified by mass spectrometry.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

While further research is needed to identify the most effective RIPR candidates for preclinical development, this approach opens an entirely new avenue for overcoming resistance to immunotherapy. We are actively securing intellectual property covering both the candidate molecules and the underlying design principles to ensure protection and future translational potential. These steps, together with ongoing validation and optimisation, will position the consortium for subsequent phases of preclinical testing and eventual partnership toward clinical application.